| Connect Hearing, Inc. | |
|
1511 Enterprise Dr, Ste A, Lynchburg, VA 24502-5751 | |
| (434) 385-0000 | |
| (434) 385-0006 |
| Full Name | Connect Hearing, Inc. |
|---|---|
| Type | Facility |
| Speciality | Hearing Aid Equipment |
| Location | 1511 Enterprise Dr, Lynchburg, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205259520 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Connect Hearing, Inc. 750 N. Commons Dr. Suite 200, Aurora, IL 60504 Ph: (630) 303-5380 | Connect Hearing, Inc. 1511 Enterprise Dr, Ste A, Lynchburg, VA 24502-5751 Ph: (434) 385-0000 |
News Archive
A new study published on October 17, 2019, in the journal EP Europace, shows that people who drink alcohol almost every day, even in small amounts, are more at risk to develop an irregular heart rhythm called atrial fibrillation (AF), which is linked to a five-fold higher risk of stroke.
Once, at the School of Nursing, grade point average and standardized test scores were all that mattered. Students hoped for the highest marks they could achieve and administrators used them as a barometer for success.
Use of most electronic media is not associated with headaches, at least not in adolescents. A study of 1025 13-17 year olds, published in the open access journal BMC Neurology, found no association between the use of computer games, mobile phones or television and the occurrence of headaches or migraines.
A new study finds wide variations in colorectal cancer stage of diagnosis and mortality, with some ethnic groups having 10 to 60 percent higher risks of stage III or IV colorectal cancer compared to non-Hispanic whites, and 20 to 30 percent higher risk of death from the disease.
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
› Verified 7 days ago